Cargando…
Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer
SIMPLE SUMMARY: Adenocarcinomas represent nearly 40% of all cancer types, and account for more than 70% of cancer-related deaths. Labyrinthin (LAB) is a novel cancer neoantigen expressed on the surface of adenocarcinoma cells of various cancer types. Several treatment strategies are being developed...
Autores principales: | Ma, Weijie, Zeng, Jie, Montoya, Dennis J., Toomey, Kyra, Zhou, Chihong, Chen, Shuai, Liu, Dingning, Babich, Michael, Radosevich, James A., Li, Tianhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913764/ https://www.ncbi.nlm.nih.gov/pubmed/36765881 http://dx.doi.org/10.3390/cancers15030924 |
Ejemplares similares
-
Topology and adenocarcinoma cell localization dataset on the labyrinthin diapeutic biomarker
por: Sharma, Ankit, et al.
Publicado: (2023) -
Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen
por: Babich, Michael, et al.
Publicado: (2022) -
High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer
por: Li, Qianping, et al.
Publicado: (2020) -
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
por: Radosevich, James A, et al.
Publicado: (2019) -
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
por: Ma, Weijie, et al.
Publicado: (2021)